Business
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide choline) extended-release tablets, previously known as DCCR, at the 2025 United in Hope: International Prader-Willi Syndrome Conference. “We believe that these data reveal critical insights on the potential benefit of VYKAT XR to important subpopulations of individuals living with PWS,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “For those individuals who are managed with strict food controls, these data suggest that they had more hyperphagia symptoms at baseline yet still saw a statistically significant, clinically meaningful benefit from treatment with VYKAT XR. These data also show that VYKAT XR can be safely administered to individuals with PWS who have pre-diabetes or diabetes, providing a benefit despite this co-morbidity.” Data are featured in two poster presentations: Diazoxide Choline Extended-Release Tablets Significantly Reduce Hyperphagia in Patients with PWS Who Are Managed with Strict Food ControlsA primary characteristic of PWS is hyperphagia, a persistent hunger that can lead to aggressive food-seeking behavior. A common practice used in the management of individuals with PWS is to restrict access to food, but this does not address the underlying symptoms of hyperphagia. This poster summarizes an analysis of participants in Soleno’s Phase 3 studies to determine if VYKAT XR can improve hyperphagia symptoms in individuals with PWS considered to be in a highly food restricted environment. After treatment with VYKAT XR, participants in the highly food-restricted group exhibited statistically significant (p ≤ 0.0001), clinically meaningful reductions in HQ-CT Total scores that were often numerically greater than those observed in the less restricted group at all post-baseline timepoints through Year 3. These data demonstrate that individuals with PWS who live with strict food controls are as likely to benefit from treatment with VYKAT XR as those who live with less strict food controls. Safety and Efficacy of Diazoxide Choline Extended-Release in Patients with PWS who Have Pre-Diabetes or DiabetesThis poster summa...